دورة المؤشرنت للتحليل الفني
50 دينار كويتي
اسهم بشائر الخير
- بادئ الموضوع بشائر الخير
- تاريخ البدء
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM)
Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrine's Cotara(R) for Treatment of Brain Cancer
Company Overview
Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody designed to bind to the DNA histone complex that is exposed by dead and dying cells found at the center of solid tumors. Cotara's targeting mechanism enables it to bind to the dying tumor cells, delivering its radioactive payload to the adjacent living tumor cells and essentially destroying the tumor from the inside out, with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (CED), an NIH-developed method that targets the specific tumor site in the brain. In a previous clinical study, a subset of patients with recurrent glioblastoma treated with Cotara achieved a median survival of 38 weeks, a 58% increase over the historical median survival time of 24 weeks for patients treated with standard of care therapy. In this study, 25% of 28 recurrent patients survived for more than a year post-treatment and 10% of patients survived for more than three years. These data are considered a promising development in this deadly disease. In addition to the Phase II trial now underway in India, a dosimetry and dose confirmation trial in glioblastoma patients at leading U.S. academic brain cancer centers is nearing completion. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
السهم للاستثمار جيد اذا نزل شوى زين عن الاسعار الحاليه ممتاز جلب بيه
Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrine's Cotara(R) for Treatment of Brain Cancer
Company Overview
Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody designed to bind to the DNA histone complex that is exposed by dead and dying cells found at the center of solid tumors. Cotara's targeting mechanism enables it to bind to the dying tumor cells, delivering its radioactive payload to the adjacent living tumor cells and essentially destroying the tumor from the inside out, with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (CED), an NIH-developed method that targets the specific tumor site in the brain. In a previous clinical study, a subset of patients with recurrent glioblastoma treated with Cotara achieved a median survival of 38 weeks, a 58% increase over the historical median survival time of 24 weeks for patients treated with standard of care therapy. In this study, 25% of 28 recurrent patients survived for more than a year post-treatment and 10% of patients survived for more than three years. These data are considered a promising development in this deadly disease. In addition to the Phase II trial now underway in India, a dosimetry and dose confirmation trial in glioblastoma patients at leading U.S. academic brain cancer centers is nearing completion. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
السهم للاستثمار جيد اذا نزل شوى زين عن الاسعار الحاليه ممتاز جلب بيه
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
نصيح من القلب
البتعاد عن الاسهم التي قيمتها قليله والفوليم قليل لان هم الملاك يتحكمون بالسهم
ام الاسهم فوليم معتدل يكون القالب معا الموشر والاخبار هذه ماحبيت ان يستفيدون من الاخوان
البتعاد عن الاسهم التي قيمتها قليله والفوليم قليل لان هم الملاك يتحكمون بالسهم
ام الاسهم فوليم معتدل يكون القالب معا الموشر والاخبار هذه ماحبيت ان يستفيدون من الاخوان
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
Mxgd 0.260 مبروك والحمد الله حقق الهدف بالسرعه
الفال للي وراه
الفال للي وراه
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
BGMO 
0ز910 مبروك والحمدلله هذه من فضل ربي
0ز910 مبروك والحمدلله هذه من فضل ربيبشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
Gfgu الدور جاي على هذه السهم باذن الله عزوجل
باذن الله عزوجلمضارب ضايع
عضو نشط
- التسجيل
- 28 سبتمبر 2008
- المشاركات
- 869
بالتوفيق
الضيف الهادي
عضو نشط
- التسجيل
- 5 فبراير 2009
- المشاركات
- 68
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
هل بالغالي بالنسب gfgu للدخول بالاسعار الحاليه واقل شوي يكون واجد زين يالغالى اناعندي احساس هذه السهم راح يطير غدا والله اعلم والسبب ان فوليم امس كان اعلى فوليم فى تاريخه وماطار كعدين يجمعون والله اعلم وانشالله يصدق احساسي ممكن يوصل الهدف 2.00 والله اعلم والله اعلم لاكن المقاومه الاولى1.2
مبروك قارب المقاومه الاولى وانشالله نشوفه فى الدقائق الاخيره يااخوان اذاواصل الصعود بهذه الطريق لحظ الفوليم العالى جد كل ماله يزيد تدريجيا انشا الله نشوف فى الايام القادمه 2.00
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
الشركه الثانبه لها خبر اليوم يطلع
ALTH - News
http://www.chartmoney.com/stockquotes.php/?ticker=alth
Allos Therapeutics, Inc. today announced the Company will hold a webcast conference call on Wednesday, September 2, 2009 to discuss the outcome of the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee meeting for FOLOTYN (pralatrexate).[/QUOTE]
Allos gets positive panel ruling, but shares slip
Allos Therapeutics stock falls despite FDA panel recommendation for Folotyn approval
By Marley Seaman, AP Health Writer
On Thursday September 3, 2009, 1:37 pm EDT
Buzz up! 0 Print
Companies:Allos Therapeutics, Inc.
NEW YORK (AP) -- Shares of Allos Therapeutics Inc. retreated Thursday, as an analyst said a Food and Drug Administration panel vote on an Allos drug was "much more contentious ... than A group of FDA advisers said the agency should approve Allos's drug Folotyn, which is intended to treat T-cell lymphoma. But JMP Securities analyst Charles Duncan, who attended the meeting, said panelists ended up discussing unexpected issues about the design of the trial, which may have caused some investors to believe the FDA will not approve Folotyn.
The stock lost 50 cents, or 6.4 percent, to $7.36 in afternoon trading. Trading of Allos shares was halted all day Wednesday.
Duncan said the experts argued about the types of patients included in a late stage study of Folotyn, as well as the design of the trial and the nature of the data Allos submitted.
"There was a very hotly contested debate on all of those issues," he said. However, the panel recommended the drug be approved in a 10 to 4 vote. In a note to clients, Duncan said that vote "clears the path for approval of the drug."
Duncan said the panel members were arguing about the different sway clinical trials can be conducted, and most were not opposed to approving Folotyn. The FDA is scheduled to make a ruling on Folotyn by Sept. 24, and while it is not required to follow the advice of its panels, it often does so.
ALTH - News
http://www.chartmoney.com/stockquotes.php/?ticker=alth
Allos Therapeutics, Inc. today announced the Company will hold a webcast conference call on Wednesday, September 2, 2009 to discuss the outcome of the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee meeting for FOLOTYN (pralatrexate).[/QUOTE]
Allos gets positive panel ruling, but shares slip
Allos Therapeutics stock falls despite FDA panel recommendation for Folotyn approval
By Marley Seaman, AP Health Writer
On Thursday September 3, 2009, 1:37 pm EDT
Buzz up! 0 Print
Companies:Allos Therapeutics, Inc.
NEW YORK (AP) -- Shares of Allos Therapeutics Inc. retreated Thursday, as an analyst said a Food and Drug Administration panel vote on an Allos drug was "much more contentious ... than A group of FDA advisers said the agency should approve Allos's drug Folotyn, which is intended to treat T-cell lymphoma. But JMP Securities analyst Charles Duncan, who attended the meeting, said panelists ended up discussing unexpected issues about the design of the trial, which may have caused some investors to believe the FDA will not approve Folotyn.
The stock lost 50 cents, or 6.4 percent, to $7.36 in afternoon trading. Trading of Allos shares was halted all day Wednesday.
Duncan said the experts argued about the types of patients included in a late stage study of Folotyn, as well as the design of the trial and the nature of the data Allos submitted.
"There was a very hotly contested debate on all of those issues," he said. However, the panel recommended the drug be approved in a 10 to 4 vote. In a note to clients, Duncan said that vote "clears the path for approval of the drug."
Duncan said the panel members were arguing about the different sway clinical trials can be conducted, and most were not opposed to approving Folotyn. The FDA is scheduled to make a ruling on Folotyn by Sept. 24, and while it is not required to follow the advice of its panels, it often does so.
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
الليله انتظرني على السحور يالغالي راحتشوف اسهم تعجبك
مضارب ضايع
عضو نشط
- التسجيل
- 28 سبتمبر 2008
- المشاركات
- 869
اخوي بشاير الخير اخووك مو طمااااع السهم باذن الله بكره في نفس من 10 لى 15 سنت ربح
الضيف الهادي
عضو نشط
- التسجيل
- 5 فبراير 2009
- المشاركات
- 68
الليله انتظرني على السحور يالغالي راحتشوف اسهم تعجبك
الله يعطيك الف عافية وموفق خير يا الغالي وناطرينك
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
BCLE سهم فيه خير باذن الله تعالى
Bio-Clean International, Inc. Forms New Construction Entity
Bio-Clean International, Inc. Forms New Construction Entity
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
الهدف الاول باذن الله تعالى 0.040 انشاءالله نشوفه غدا
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
السهم الثاني
0.0550 0.0080 (17.02%) Auto Max Group Holdings, Inc. (BEHL.PK
BioCentric Submits a RFP for Comfort Systems to Build the Algae Pro Photobioreactor Solution in Death Valley Junction
0.0550 0.0080 (17.02%) Auto Max Group Holdings, Inc. (BEHL.PK
BioCentric Submits a RFP for Comfort Systems to Build the Algae Pro Photobioreactor Solution in Death Valley Junction
الضيف الهادي
عضو نشط
- التسجيل
- 5 فبراير 2009
- المشاركات
- 68
مشكور يا الغالي الف مرة على هالمجهود الطيب والله يفتحلك ابواب رزقه. شرايك مو كانه axvc اشتغل قطاره
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
مشكور يا الغالي الف مرة على هالمجهود الطيب والله يفتحلك ابواب رزقه. شرايك مو كانه axvc اشتغل قطاره
مشكووووووور يالغالي حب لاخيك ما تحب لنفس هذه هو مبدئي
نعم يالغالي ممكن تشوف اليوم شغل عدل
يوقال لاحدا السلف ماهو سر قبولك وتوفيقك في التجاره يقول انى اكثر الدعاء الى الناس اكثرمن نفسي ( ويقول الله عزوجل ولك مثله بمعنى الحديث والحديث مختصر )
بشائر الخير
عضو نشط
- التسجيل
- 18 سبتمبر 2007
- المشاركات
- 247
السهم الثاني
0.0550 0.0080 (17.02%) auto max group holdings, inc. (behl.pk
biocentric submits a rfp for comfort systems to build the algae pro photobioreactor solution in death valley junction
السهم ممكن ينطلق اليوم انتبهله لاتخليه
دورة المؤشرنت للتحليل الفني
50 دينار كويتي